Save on Dostarlimab-GXLY with Coupons, Discounts & Savings Programs

Dostarlimab-GXLY is available as a 500 mg/10 mL (50 mg/mL) injection for IV use.

• Dostarlimab-GXLY is a monoclonal antibody that is used to treat endometrial cancer and Mismatch repair deficient recurrent or advanced solid tumors

Dostarlimab-GXLY is a type of immunotherapy called an immune checkpoint inhibitor. PD-1 is a type of checkpoint protein found on T cells, which are immune system cells that roam throughout the body looking for signs of disease or infection. PD-L1 is another checkpoint protein found on many healthy cells in the body. When PD-1 binds to PD-L1, it stops T cells from killing a cell. Still, some cancer cells have a lot of PD-L1 on their surface, which stops T cells from killing these cancer cells. An immune checkpoint inhibitor medicine like Dostarlimab-GXLY that stops PD-1 from binding to PD-L1 allows T cells to attack the cancer cells.

• Dostarlimab-GXLY in combination with carboplatin and paclitaxel, for dMMR or MSI-H primary advanced or recurrent endometrial cancer: 500 mg every 3 weeks for 6 doses followed by 1,000 mg monotherapy every 6 weeks
• Dostarlimab-GXLY, as a single agent, for dMMR recurrent or advancedendometrial cancer: 500 mg every 3 weeks for 4 doses followed by 1,000 mg every 6 weeks. (2.2)
• Dostarlimab-GXLY, as a single agent, for dMMR recurrent or advanced solid tumors: 500 mg every 3 weeks for 4 doses followed by 1,000 mg every 6 weeks

Dostarlimab-GXLY is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Dostarlimab-GXLY:

• Rash
• Diarrhea
• Hypothyroidism
• Hypertension
• Decreased neutrophils, hemoglobin, lymphocytes and white blood cells
• Increased glucose
• Decreased sodium
• Decreased platelets

Serious side effects are rare with Dostarlimab-GXLY. Call or see your healthcare provider right away if you develop any of the following:

• Lung problems
• Intestinal problems
• Liver problems
• Skin problems
• Hormone gland problems
• Kidney problems

• There are no major drug interactions listed for Dostarlimab-GXLY. However, always let your physician and pharmacist know about any other medications or supplements (including prescribed and over-the-counter medications, vitamins, and dietary or herbal supplements) that you are currently taking

Various FDA-approved generic manufacturers

Based on its mechanism of action, Dostarlimab-GXLY can cause fetal harm when administered to a pregnant woman. If you can become pregnant, you should use effective contraception during treatment with Dostarlimab-GXLY and for 4 months after the last dose.

• Jemperli